• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23368 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2023     National Institute for Health and Care Excellence (NICE) Minimally invasive fusionless posterior-approach surgery to correct idiopathic scoliosis in children and young people. NICE interventional procedures guidance 765
2023     National Institute for Health and Care Excellence (NICE) Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis when surgery is not an option. NICE interventional procedures guidance 764
2023     National Institute for Health and Care Excellence (NICE) Radiofrequency denervation for osteoarthritic knee pain. NICE interventional procedures guidance 767
2023     National Institute for Health and Care Excellence (NICE) Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. NICE interventional procedures guidance 766
2023     National Institute for Health and Care Excellence (NICE) Irreversible electroporation for treating prostate cancer. NICE interventional procedures guidance 768
2023     National Institute for Health and Care Excellence (NICE) Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium for aortic valve disease. NICE interventional procedures guidance 769
2023     National Institute for Health and Care Excellence (NICE) Cryotherapy for chronic rhinitis. NICE interventional procedures guidance 771
2023     National Institute for Health and Care Excellence (NICE) Transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 770
2023     National Institute for Health and Care Excellence (NICE) Removal, preservation and reimplantation of ovarian tissue for restoring fertility after gonadotoxic treatment. NICE interventional procedures guidance 772
2023     National Institute for Health and Care Excellence (NICE) Percutaneous deep venous arterialisation for chronic limb-threatening ischaemia. NICE interventional procedures guidance 773
2023     National Institute for Health and Care Excellence (NICE) Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. NICE interventional procedures guidance 774
2023     National Institute for Health and Care Excellence (NICE) Extracorporeal carbon dioxide removal for acute respiratory failure. NICE interventional procedures guidance 776
2023     National Institute for Health and Care Excellence (NICE) Biodegradable subacromial spacer insertion for rotator cuff tears. NICE interventional procedures guidance 775
2023     National Institute for Health and Care Excellence (NICE) Percutaneous transarterial carotid artery stent placement for asymptomatic extracranial carotid stenosis. NICE interventional procedures guidance 777
2023     National Institute for Health and Care Excellence (NICE) Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism. NICE interventional procedures guidance 778
2023     National Institute for Health and Care Excellence (NICE) Middle meningeal artery embolisation for chronic subdural haematomas. NICE interventional procedures guidance 779
2023     The Danish Health Technology Council (DHTC) [Assessment of pocket-sized handheld ultrasound devices for point-of-care examination of patients in emergency departments]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for risdiplam acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version1.0) – Second addendum to Commission A21-131]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Burnout: Can yoga help cope?]
2023     Haute Autorite de sante (HAS) [2023 update: clinical utility of genomic signatures in early-stage HR-positive/HER2-negative breast cancer]
2023     Haute Autorite de sante (HAS) [Assessment of the Endotest® saliva test in complex endometriosis diagnosis situations]
2023     Haute Autorite de sante (HAS) [Assessment of the exhaled nitric oxide measurement for asthma management]
2023     The Danish Health Technology Council (DHTC) [Use of artificial intelligence as clinical decision-support in colonoscopy for the diagnosis of neoplastic disease]
2023     Andalusian Health Technology Assessment Area (AETSA) [Clinical effectiveness and safety of newborn screening for spinal muscular atrophy. Systematic review]
2023     The Danish Health Technology Council (DHTC) [Assessment concerning glucose monitoring for the treatment of adult patients with type 1 diabetes]
2023     National Evidence-based Healthcare Collaborating Agency (NECA) [Low-level light therapy for primary dysmenorrhea]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Contraception: comparison of hormonal coils and copper coils]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Restless legs syndrome: can the symptoms be alleviated through non-medicinal procedures?]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fibromatoses of the hand (Dupuytren's disease) and / or foot (Ledderhose's disease): do those affected benefit from radiation therapy?]
2023     National Institute for Health and Care Excellence (NICE) Targeted-release budesonide for treating primary IgA nephropathy. NICE technology appraisal guidance 937
2023     National Institute for Health and Care Excellence (NICE) Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal). NICE technology appraisal guidance 938
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 939
2023     National Institute for Health and Care Excellence (NICE) Ravulizumab for treating generalised myasthenia gravis (terminated appraisal). NICE technology appraisal guidance 940
2023     National Institute for Health and Care Excellence (NICE) Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal). NICE technology appraisal guidance 941
2023     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic kidney disease. NICE technology appraisal guidance 942
2023     National Institute for Health and Care Excellence (NICE) Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes. NICE technology appraisal guidance 943
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of bimekizumab (Bimzelx)]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of gefapixant (Lyfnua)]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of clazosentan (Pivlaz)]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of andexanet alfa (Ondexxya)]
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) (Cost-effectiveness evaluation of Valbenazine (Dysval) for tardive dyskinesia)
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) [Cost-effectiveness evaluation of Efgartigimod Alfa (Vyvgart)]
2023     HTA Region Stockholm [Effects of nonsteroidal anti-inflammatory drugs (NSAID) on risk of exacerbation of disease in patients with inflammatory bowel disease (IBD)]
2023     National Institute for Health and Care Excellence (NICE) Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal). NICE technology appraisal guidance 936
2023     National Institute for Health and Care Excellence (NICE) Secukinumab for treating moderate to severe hidradenitis suppurativa. NICE technology appraisal guidance 935
2023     National Institute for Health and Care Excellence (NICE) Foslevodopa–foscarbidopa for treating advanced Parkinson's with motor symptoms. NICE technology appraisal guidance 934
2023     National Institute for Health and Care Excellence (NICE) Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (terminated appraisal). NICE technology appraisal guidance 933
2023     National Institute for Health and Care Excellence (NICE) Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal). NICE technology appraisal guidance 932
2023     National Institute for Health and Care Excellence (NICE) Zanubrutinib for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 931
2023     National Institute for Health and Care Excellence (NICE) Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments. NICE technology appraisal guidance 930
2023     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. NICE technology appraisal guidance 929
2023     National Institute for Health and Care Excellence (NICE) Cabozantinib for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine. NICE technology appraisal guidance 928
2023     National Institute for Health and Care Excellence (NICE) Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 927
2023     National Institute for Health and Care Excellence (NICE) Baricitinib for treating severe alopecia areata. NICE technology appraisal guidance 926
2023     National Institute for Health and Care Excellence (NICE) Mirikizumab for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 925
2023     National Institute for Health and Care Excellence (NICE) Tirzepatide for treating type 2 diabetes. NICE technology appraisal guidance 924
2023     National Institute for Health and Care Excellence (NICE) Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus (terminated appraisal). NICE technology appraisal guidance 923
2023     National Institute for Health and Care Excellence (NICE) Daridorexant for treating long-term insomnia. NICE technology appraisal guidance 922
2023     National Institute for Health and Care Excellence (NICE) Ruxolitinib for treating polycythaemia vera. NICE technology appraisal guidance 921
2023     National Institute for Health and Care Excellence (NICE) Tofacitinib for treating active ankylosing spondylitis. NICE technology appraisal guidance 920
2023     National Institute for Health and Care Excellence (NICE) Rimegepant for treating migraine. NICE technology appraisal guidance 919
2023     National Institute for Health and Care Excellence (NICE) Bimekizumab for treating axial spondyloarthritis. NICE technology appraisal guidance 918
2023     National Institute for Health and Care Excellence (NICE) Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable. NICE technology appraisal guidance 917
2023     National Institute for Health and Care Excellence (NICE) Bimekizumab for treating active psoriatic arthritis. NICE technology appraisal guidance 916
2023     National Institute for Health and Care Excellence (NICE) Pegunigalsidase alfa for treating Fabry disease. NICE technology appraisal guidance 915
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 914
2023     National Institute for Health and Care Excellence (NICE) Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy. NICE technology appraisal guidance 913
2023     National Institute for Health and Care Excellence (NICE) Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease. NICE technology appraisal guidance 912
2023     National Institute for Health and Care Excellence (NICE) Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 911
2023     National Institute for Health and Care Excellence (NICE) Semaglutide for managing overweight and obesity in young people aged 12 to 17 years (terminated appraisal). NICE technology appraisal guidance 910
2023     National Institute for Health and Care Excellence (NICE) Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 909
2023     National Institute for Health and Care Excellence (NICE) Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy. NICE technology appraisal guidance 908
2023     National Institute for Health and Care Excellence (NICE) Deucravacitinib for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 907
2023     National Institute for Health and Care Excellence (NICE) Rimegepant for preventing migraine. NICE technology appraisal guidance 906
2023     National Institute for Health and Care Excellence (NICE) Upadacitinib for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 905
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancer. NICE technology appraisal guidance 904
2023     National Institute for Health and Care Excellence (NICE) Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 903
2023     National Institute for Health and Care Excellence (NICE) Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction. NICE technology appraisal guidance 902
2023     National Institute for Health and Care Excellence (NICE) Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal). NICE technology appraisal guidance 901
2023     National Institute for Health and Care Excellence (NICE) Tixagevimab plus cilgavimab for preventing COVID-19. NICE technology appraisal guidance 900
2023     National Institute for Health and Care Excellence (NICE) Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal). NICE technology appraisal guidance 899
2023     National Institute for Health and Care Excellence (NICE) Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 898
2023     National Institute for Health and Care Excellence (NICE) Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma. NICE technology appraisal guidance 897
2023     National Institute for Health and Care Excellence (NICE) Bulevirtide for treating chronic hepatitis D. NICE technology appraisal guidance 896
2023     National Institute for Health and Care Excellence (NICE) Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy. NICE technology appraisal guidance 895
2023     National Institute for Health and Care Excellence (NICE) Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma. NICE technology appraisal guidance 894
2023     National Institute for Health and Care Excellence (NICE) Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over. NICE technology appraisal guidance 893
2023     National Institute for Health and Care Excellence (NICE) Mosunetuzumab for treating relapsed or refractory follicular lymphoma. NICE technology appraisal guidance 892
2023     National Institute for Health and Care Excellence (NICE) Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 891
2023     National Institute for Health and Care Excellence (NICE) Difelikefalin for treating pruritus in people having haemodialysis. NICE technology appraisal guidance 890
2023     National Institute for Health and Care Excellence (NICE) Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 889
2023     National Institute for Health and Care Excellence (NICE) Risankizumab for previously treated moderately to severely active Crohn's disease. NICE technology appraisal guidance 888
2023     National Institute for Health and Care Excellence (NICE) Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 887
2023     National Institute for Health and Care Excellence (NICE) Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy. NICE technology appraisal guidance 886
2023     National Institute for Health and Care Excellence (NICE) Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer. NICE technology appraisal guidance 885
2023     National Institute for Health and Care Excellence (NICE) Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal). NICE technology appraisal guidance 884
2023     National Institute for Health and Care Excellence (NICE) Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma. NICE technology appraisal guidance 883
2023     National Institute for Health and Care Excellence (NICE) Voclosporin with mycophenolate mofetil for treating lupus nephritis. NICE technology appraisal guidance 882
2023     National Institute for Health and Care Excellence (NICE) Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatments. NICE technology appraisal guidance 881
2023     National Institute for Health and Care Excellence (NICE) Tezepelumab for treating severe asthma. NICE technology appraisal guidance 880